IL6 and cancer: There is some evidence that in cancers with PIK3CA mutations, such as endometrioid and clear cell ovarian cancers, upregulation of nuclear factor-kappaB (NF-κB) pathways may drive the expression of IL-6, perhaps relating known associations between increased NF-κB expression and poor prognosis in ovarian cancer to mechanisms underlying associations with thrombocytosis [68,69,70,71,72,73,74].